From: High-dose thiotepa-related neurotoxicity and the role of tramadol in children
n | NAE (%) | univariate Pa | univariate OR (95% CI) | multivariate Pb | multivariate OR (95% CI) | |
---|---|---|---|---|---|---|
Gender | ||||||
Boys | 145 | 24 (17%) | ||||
Girls | 106 | 22 (21%) | 0.41 | 1.3 (0.7–2.5) | ||
Age | ||||||
No NAE | 205 | 9.3 (6.3)f | ||||
Yes NAE | 46 | 8.6 (5.2)f | 0.48c | |||
Race | ||||||
Caucasian | 186 | 31 (17%) | ||||
African | 40 | 9 (23%) | 0.51e | |||
Others | 25 | 6 (24%) | ||||
Brain tumour | ||||||
No | 135 | 18 (13%) | 1 | 1 | ||
Yes | 116 | 28 (24%) | 0.03 | 2.1 (1.1–4.0) | 0.04 | 2.2 (1.0–4.6) |
Neurological disorder at baseline | ||||||
No | 230 | 38 (17%) | 1 | 1 | ||
Yes | 20 | 8 (40%) | 0.02 | 3.4 (1.3–8.8) | 0.08 | 2.7 (0.9–8.4) |
History of seizure | ||||||
No | 238 | 42 (18%) | 1 | |||
Yes | 13 | 4 (31%) | 0.27 | 2.1 (0.6–7.1) | ||
Thiotepa regimen | ||||||
600 mg/m2 | 129 | 18 (14%) | ||||
720 mg/m2 | 76 | 17 (22%) | 0.18e | |||
900 mg/m2 | 46 | 11 (24%) | ||||
Alizaprided | ||||||
No | 126 | 19 (15%) | 1 | 1 | ||
Yes | 94 | 25 (27%) | 0.04 | 2.0 (1.0–4.0) | 0.13 | 1.7 (0.8–3.6) |
Aprepitantd | ||||||
No | 213 | 41 (19%) | 1 | |||
Yes | 7 | 3 (43%) | 0.14 | 3.1 (0.7–14.6) | ||
Antipsychoticd | ||||||
No | 180 | 34 (19%) | 1 | |||
Yes | 40 | 10 (25%) | 0.39 | 1.4 (0.6–3.2) | ||
Proton Pump Inhibitord | ||||||
No | 213 | 43 (20%) | 1 | |||
Yes | 7 | 1 (14%) | 1 | 0.7 (0.1–5.6) | ||
Histamine H2-receptor antagonistd | ||||||
No | 215 | 42 (20%) | 1 | |||
Yes | 5 | 2 (40%) | 0.26 | 2.7 (0.4–17) | ||
Simple analgesicsd | ||||||
i.e. acetaminophen, nefopam | ||||||
No | 144 | 20 (13%) | 1 | |||
Yes | 76 | 14 (18%) | 0.40 | 1.4 (0.7–3.0) | ||
Weak opioidsd | ||||||
i.e. tramadol, codeine, dextropropoxyphen | ||||||
No | 167 | 20 (12%) | 1 | 1 | ||
Yes | 53 | 24 (45%) | 0.0001 | 6.1 (3.0–12.4) | 0.0001 | 6.3 (3.0–13.4) |
Strong opioidsd | ||||||
i.e. morphine, pethidine | ||||||
No | 211 | 44 (21%) | 1 | |||
Yes | 9 | 4 (44%) | 0.09 | 3.0 (0.8–11.8) |